Bibliography for Item 2 in BGP: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Primary Links==
==Used Resources==


*Alonso-Zaldivar, Ricardo, “FDA pledges openness on gene-altered products,” wtop.com, January 15, 2009. Last Accessed March 14, 2009. http://www.wtopnews.com/?nid=106&sid=1575167
*Alonso-Zaldivar, Ricardo, “FDA pledges openness on gene-altered products,” wtop.com, January 15, 2009. Last Accessed March 14, 2009. http://www.wtopnews.com/?nid=106&sid=1575167
Line 60: Line 60:
** stock ticker for biotech companies
** stock ticker for biotech companies


==Secondary links==
* Jaffe,A . M. Trajtenberg, R. Henderson. 1993. Geographiclo calization of knowledge spillovers as evidenced by patent citations. Quart. J. Econom. 63 577-598.
 
* Robert Kaiser and Michael Liecke, “Regional Knowledge Dynamics in the Biotechnology Industry: A Conceptual Framework for Micro-Level Analysis” University of Munich
 
* Helena Yli-Renko, Erkko Autio, Harry J. Sapienza , “Social Capital, Knowledge Acquisition, and Knowledge Exploitation in Young Technology-Based Firms,” Strategic Management Journal, Vol. 22, No. 6/7, Special Issue: Strategic Entrepreneurship: Entrepreneurial Strategies for Wealth Creation (Jun. - Jul., 2001), pp. 587-613
 
* Joel A. C. Baum, Tony Calabrese, Brian S. Silverman , “Don't Go It Alone: Alliance Network Composition and Startups' Performance in Canadian Biotechnology,” Strategic Management Journal, Vol. 21, No. 3, Special Issue: Strategic Networks (Mar., 2000), pp. 267-294
 
*NCBI, "Our Mission," May 21 2004, http://www.ncbi.nlm.nih.gov/About/glance/ourmission.html
 
*NCBI, "Programs and Activities," May 21 2004, http://www.ncbi.nlm.nih.gov/About/glance/programs.html
 
*NCBI, "Human Genome Resources," http://www.ncbi.nlm.nih.gov/genome/guide/human/
 
*Bownas, Jennifer, "Accessing records in NCBI's sequence databases" U.S. Department of Energy Biological and Environmental Research program, January 2 2003, http://www.ornl.gov/sci/techresources/Human_Genome/posters/chromosome/sequence.shtml
 
*NCBI, "Sequence Identifiers: A Historical Note," June 14 2004, http://www.ncbi.nlm.nih.gov/Sitemap/sequenceIDs.html
 
*NIH, "National Institutes of Health Public Access," http://publicaccess.nih.gov/
 
*Science Commons, "NIH Mandate Made Permanent" March 17 2009 http://sciencecommons.org/weblog/archives/2009/03/17/nih-mandate-made-permanent/
 
*NCBI, "The NCBI Handbook" http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=handbook
 
*NIH Working Group on Research Tools, "Report of the National Institutes of Health (NIH) Working Group on Research Tools" June 4 1998, http://www.nih.gov/news/researchtools/
 
*Trans-NIH Mouse Initiatives, "Frequently Asked Questions (FAQs) and Answers" http://www.nih.gov/science/models/mouse/sharing/5.html
 
*Ladas & Parry "Patentability of Process Claims in the United States," August 14 1996 http://www.ladas.com/Patents/Biotechnology/Durden-ProcessClaims.html
 
==Unused Resources==


* New York Biotechnology Association, <http://www.nyba.org/>
* New York Biotechnology Association, <http://www.nyba.org/>
Line 111: Line 141:
*''Common ground on the critical path'' Nature Reviews Drug Discovery Vol. 5, No. 267,April 2006, <http://www.nature.com/nrd/journal/v5/n4/abs/nrd2019.html>
*''Common ground on the critical path'' Nature Reviews Drug Discovery Vol. 5, No. 267,April 2006, <http://www.nature.com/nrd/journal/v5/n4/abs/nrd2019.html>


==Books: (some you can read online)==


*Friedman, Yali. ''Building Biotechnology'', Thinkbiotech: 2006. <http://www.amazon.com/Building-Biotechnology-Business-Regulations-Politics/dp/0973467665/ref=si3_rdr_bb_product>
*Friedman, Yali. ''Building Biotechnology'', Thinkbiotech: 2006. <http://www.amazon.com/Building-Biotechnology-Business-Regulations-Politics/dp/0973467665/ref=si3_rdr_bb_product>
Line 127: Line 156:
*Acharya, Rohini, ''The Emergence and Growth of Biotechnology: Experiences in Industrialized and Developing Countries''. Cheltanham, UK: Edward Elgar, 1999.
*Acharya, Rohini, ''The Emergence and Growth of Biotechnology: Experiences in Industrialized and Developing Countries''. Cheltanham, UK: Edward Elgar, 1999.


==Others==
*Office of Biotechnology Activities, ''Welcome to OBA'', http://oba.od.nih.gov/oba/index.html
*Office of Biotechnology Activities, ''Welcome to OBA'', http://oba.od.nih.gov/oba/index.html


==Blogs==
*''Patent Baristas'', http://patentbaristas.com/
*''Patent Baristas'', http://patentbaristas.com/



Latest revision as of 11:23, 3 May 2009

Used Resources

  • Council for Entrepreneurial Development, "2007 CED North Carolina Venture Report." 2007.
  • Gaisford, James D., and Jill E. Hobbs, William A. Kerr, Nicholas Perdikis, Mari D. Plunkett, The Economics of Biotechnology. Cheltenham, UK. Edward Elgar, 2001.
  • Guo, Re-Jing, Baruch Lev, and Nan Zhou, “Competitive Costs of Disclosure by Biotech IPOs” Journal of Accounting Research, Vo. 42 No. 2 May 2004
  • Kalil, Thomas, University-Industry Partnerships in the Life Sciences: A University of California, Berkeley Perspective, in Biotechnology: Essays from its Heartland, Lynn Yarris, ed. San Francisco: BASIC, 2004.
  • McKelvey, Maureen, Annika Rickne and Jens Laage-Hellman, “Stylized facts about innovation processes in modern biotechnology,” in The Economic Dynamics of Modern Biotechnology. Cheltenham, UK: Edward Elgar, 2004.
    • Information about innovation processes
  • Oliver, Amalya L., "University-Based Biotechnology Spin-Offs," in Handbook of Bioentrepreneurship, Holger Patzelt and Thomas Brenner, eds. New York: Springer, 2008
  • Oliver, Richard, The Coming Biotech Age: The Business of Bio-Materials, New York: McGraw-Hill, 2000.
  • Open Source Biotechnology Project, Intellectual Property and Industry Structure, http://rsss.anu.edu.au/~janeth/IPIndust.html, 1999
    • problems of intellectual property regimes in Biotech, with specific reference to anticommons problems in the Agriculture Biotech industry
  • Penhoet, Ed. "The Biotechnology Industry from Birth to Adolescence", in Biotechnology: Essays from its Heartland, Lynn Yarris, ed. San Francisco: BASIC, 2004.
  • Pisano, Gary P., "Can Science Be a Business? Lessons from Biotech" Harvard Business Review, Oct2006, Vol. 84 Issue 10, p114-125
  • Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech, Boston: Harvard Business School Press, 2006.
  • Jaffe,A . M. Trajtenberg, R. Henderson. 1993. Geographiclo calization of knowledge spillovers as evidenced by patent citations. Quart. J. Econom. 63 577-598.
  • Robert Kaiser and Michael Liecke, “Regional Knowledge Dynamics in the Biotechnology Industry: A Conceptual Framework for Micro-Level Analysis” University of Munich
  • Helena Yli-Renko, Erkko Autio, Harry J. Sapienza , “Social Capital, Knowledge Acquisition, and Knowledge Exploitation in Young Technology-Based Firms,” Strategic Management Journal, Vol. 22, No. 6/7, Special Issue: Strategic Entrepreneurship: Entrepreneurial Strategies for Wealth Creation (Jun. - Jul., 2001), pp. 587-613
  • Joel A. C. Baum, Tony Calabrese, Brian S. Silverman , “Don't Go It Alone: Alliance Network Composition and Startups' Performance in Canadian Biotechnology,” Strategic Management Journal, Vol. 21, No. 3, Special Issue: Strategic Networks (Mar., 2000), pp. 267-294

Unused Resources


  • Acharya, Rohini, The Emergence and Growth of Biotechnology: Experiences in Industrialized and Developing Countries. Cheltanham, UK: Edward Elgar, 1999.

Navigation

Give an overall picture of the BGP field
Biotechnology_-_Genomic_and_Proteomics